Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
WALTHAM, Mass., Oct. 09, 2017 -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update.
Conference Call Information:
Date: Thursday, November 2, 2017
Time: 4:30 p.m. ET
Domestic Dial-in Number: (866) 323-7965
International Dial-in Number: (346) 406-0961
Conference ID: 96777747
Live webcast: https://edge.media-server.com/m6/p/5c3izimp
A replay of the conference call/webcast will be available from November 2, 2017 at 7:30 p.m. ET until November 9, 2017 at 6:30 p.m. ET. To access the replay, dial (855) 859-2056 for U.S. or (404) 537-3406 for International. The replay conference ID is 96777747.
The live audio webcast of the call can be accessed from the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be also available for 14 days. The full text of the announcement and financial results will also be available on the Company's website.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS™ (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. Radius’ clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women; and, RAD140, a non-steroidal, selective androgen receptor modulator (SARM), under investigation for potential use in hormone receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor / Media Relations Contact:
Alex Fudukidis
Tel: (646) 942-5632
Email: [email protected]
